Bipolar Disorder: Clinical Trials

12 trials for Bipolar Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated, 2 unknown, 2 withdrawn. 12 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 112Completed 5, Terminated 2, Unknown 2, Withdrawn 2, Active not recruiting 1

Follow Bipolar Disorder: new trials by email Literature Review of Bipolar Disorder trials Research Report on Bipolar Disorder

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Long-term Potentiation Disruption Underlying Cognitive Impairment in ECT
Electroconvulsive Therapy - Major Depressive Disorder, Bipolar Disorder II
Early Phase 1WithdrawnUniversity of New Mexico2025-01-212026-01-21
Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues
Decompartmentalization Framework, Liquid Herbal TInctures, Mental Imagery - Schizoaffective Disorder, Bipolar Type, Bipolar Disorder
Early Phase 1UnknownThe Essence of Integrative Health and Medicine Practice302024-10-102024-08-12
Pulse Width 0.15ms vs 0.30ms in Electroconvulsive Therapy
Electroconvulsive therapy - Major Depressive Disorder, Bipolar Depression
Early Phase 1UnknownCharles University, Czech Republic402022-01-182022-07-20
Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers
Dronabinol, Epidiolex, Placebos - Bipolar Disorder
Early Phase 1TerminatedUniversity of California, San Diego192021-09-012024-05-10
Treatment of Bipolar Depression With Pentoxifylline
Pentoxifylline 400 MG - Bipolar Depression
Early Phase 1CompletedUniversity Health Network, Toronto62021-07-122022-04-15
Candesartan as an Adjunctive Treatment for Bipolar Depression
Candesartan, Placebo - Bipolar Disorder Depression
Early Phase 1WithdrawnThe University of Texas Health Science Center, Houston2020-10-012022-04-27
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
Xenon, Nitrogen gas - Major Depressive Disorder, Bipolar Depression
Early Phase 1CompletedMassachusetts General Hospital132019-12-052026-10-09
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
Ketamine - Major Depressive Disorder, Treatment Resistant Depression
Early Phase 1Active not recruitingMayo Clinic182019-01-032026-07-02
Brain Imaging to Understand the Role of Inflammation in N-Acetyl Cysteine (NAC) Treatment of Bipolar Depression
N-acetyl cysteine (NAC) - Bipolar Disorder, Depression
Early Phase 1CompletedMartin Lan32018-11-012021-08-05
Nitrous TRD Bipolar Depression
Nitrous Oxide, Placebo - Treatment- Resistant Bipolar Disorder, Bipolar Disorder
Early Phase 1TerminatedWashington University School of Medicine12016-03-252019-07-05
Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.
Ketamine, Midazolam, Treatment as usual (TAU) - Major Depressive Disorder, Bipolar I Disorder
Early Phase 1CompletedSunnybrook Health Sciences Centre92016-01-012017-07-26
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
D-cycloserine, DCS or placebo - Schizophrenia, Bipolar Disorder
Early Phase 1CompletedMclean Hospital22015-09-272017-09-19

Narrower conditions

Depressive Disorder, Major (5)  ·  Depression (3)  ·  Psychotic Disorders (2)  ·  Anxiety Disorders (1)  ·  Attention Deficit Disorder with Hyperactivity (1)  ·  Cognitive Dysfunction (1)  ·  Dementia (1)  ·  Depressive Disorder, Treatment-Resistant (1)  ·  Disease (1)  ·  Dissociative Disorders (1)  ·  Fatigue (1)  ·  Fatigue Syndrome, Chronic (1)  ·  Inflammation (1)  ·  Psychological Well-Being (1)

Broader conditions

Bipolar and Related Disorders (12)  ·  Mental Disorders (12)  ·  Mood Disorders (12)  ·  Depressive Disorder (5)  ·  Behavior (4)  ·  Behavioral Symptoms (3)  ·  Neurocognitive Disorders (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (2)  ·  Attention Deficit and Disruptive Behavior Disorders (1)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Chronic Disease (1)  ·  Cognition Disorders (1)

Interventions

Ketamine (2)  ·  Acetylcysteine (1)  ·  Breathing Exercises (1)  ·  Cannabidiol (1)  ·  Cycloserine (1)  ·  Dietary Supplements (1)  ·  Dronabinol (1)  ·  Electroconvulsive Therapy (1)  ·  Meditation (1)  ·  Midazolam (1)  ·  Mindfulness (1)  ·  Music Therapy (1)  ·  Nitrogen (1)  ·  Nitrous Oxide (1)  ·  Pentoxifylline (1)

Sponsors

Charles University, Czech Republic (1)  ·  Martin Lan (1)  ·  Massachusetts General Hospital (1)  ·  Mayo Clinic (1)  ·  Mclean Hospital (1)  ·  Sunnybrook Health Sciences Centre (1)  ·  The Essence of Integrative Health and Medicine Practice (1)  ·  The University of Texas Health Science Center, Houston (1)  ·  University Health Network, Toronto (1)  ·  University of California, San Diego (1)  ·  University of New Mexico (1)  ·  Washington University School of Medicine (1)

Countries

United States (7)  ·  Canada (2)  ·  Czechia (1)

Top investigators

Andrew Nierenberg, MD (1)  ·  Balwinder Singh, MD, MS (1)  ·  Ben Palanca, MD (1)  ·  Deborah L. Levy, Ph.D. (1)  ·  Faith A Richardson, BSW, MPA, PhD (1)  ·  Joshua D Rosenblat, MD, MSc (1)  ·  Marsal Sanches, MD PhD (1)  ·  William Perry, PhD (1)

Results publications

PMID 15474895, PMID 31279534, PMID 33933839, PMID 34973601, PMID 35738038

NIH funding

P20GM109089 (1), R01DA043535 (1)